FOLD
Amicus Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About FOLD
Amicus Therapeutics, Inc.
A biotech company that develops small molecule drugs to treat Fabry, Gaucher and Pompe diseases
Biological Technology
02/04/2002
05/31/2007
NASDAQ Stock Exchange
499
12-31
Common stock
47 Hulfish Street, Princeton, NJ 08542
--
Amicus Therapeutics, Inc., was incorporated under the laws of the State of Delaware on February 4, 2002. The company is a global, patient-centric biotechnology company focused on discovering, developing and delivering new drugs for rare diseases. The company seeks to provide the highest quality therapies that have the potential to phase out current therapies, provide significant benefits to patients, and become first class or first class. The two therapies the company has marketed are Galafold, the first oral monotherapy for Fabry disease patients with compliant gene variants, and Pombiliti + Opfolda, a novel therapy designed to increase active enzyme uptake in key disease-related tissues in adults with late-onset Pompe disease.
Company Financials
EPS
FOLD has released its 2024 Q4 earnings. EPS was reported at 0.09, versus the expected 0.09, meeting expectations. The chart below visualizes how FOLD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FOLD has released its 2024 Q4 earnings report, with revenue of 149.71M, reflecting a YoY change of 30.09%, and net profit of 14.74M, showing a YoY change of 143.55%. The Sankey diagram below clearly presents FOLD’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
